These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32126120)

  • 21. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment.
    Saloner B; Stoller KB; Barry CL
    Psychiatr Serv; 2016 Jun; 67(6):676-9. PubMed ID: 26927578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment.
    Knudsen HK; Studts JL
    J Behav Health Serv Res; 2019 Jan; 46(1):151-163. PubMed ID: 30069622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
    Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN
    J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
    Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
    J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment Approaches for Opioid Use Disorder Offered in US Substance Use Treatment Facilities.
    Park TW; Shuey B; Liebschutz J; Cantor J; Anderson TS
    JAMA; 2024 Aug; 332(6):502-504. PubMed ID: 38990551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.
    Bonhomme J; Shim RS; Gooden R; Tyus D; Rust G
    J Natl Med Assoc; 2012; 104(7-8):342-50. PubMed ID: 23092049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Marcus R; Pykalo I; Madden L; Filippovich S; Dvoriak S; Altice FL
    J Subst Abuse Treat; 2018 Apr; 87():1-8. PubMed ID: 29471921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
    Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
    J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment.
    Reimer J; Vogelmann T; Trümper D; Scherbaum N
    Subst Abuse Treat Prev Policy; 2019 Dec; 14(1):57. PubMed ID: 31842942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of costs and utilization among buprenorphine and methadone patients.
    Barnett PG
    Addiction; 2009 Jun; 104(6):982-92. PubMed ID: 19466922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.
    Krawczyk N; Picher CE; Feder KA; Saloner B
    Health Aff (Millwood); 2017 Dec; 36(12):2046-2053. PubMed ID: 29200340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost of provision of opioid substitution therapy provision in Tijuana, Mexico.
    Burgos JL; Cepeda JA; Kahn JG; Mittal ML; Meza E; Lazos RRP; Vargas PC; Vickerman P; Strathdee SA; Martin NK
    Harm Reduct J; 2018 May; 15(1):28. PubMed ID: 29792191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use and misuse of opioid agonists in opioid addiction.
    Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
    Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States.
    Goedel WC; Shapiro A; Cerdá M; Tsai JW; Hadland SE; Marshall BDL
    JAMA Netw Open; 2020 Apr; 3(4):e203711. PubMed ID: 32320038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees.
    Stein BD; Dick AW; Sorbero M; Gordon AJ; Burns RM; Leslie DL; Pacula RL
    Subst Abus; 2018; 39(4):419-425. PubMed ID: 29932847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine.
    Clark RE; Samnaliev M; Baxter JD; Leung GY
    Health Aff (Millwood); 2011 Aug; 30(8):1425-33. PubMed ID: 21821560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
    Sharma A; Kelly SM; Mitchell SG; Gryczynski J; O'Grady KE; Schwartz RP
    Curr Psychiatry Rep; 2017 Jun; 19(6):35. PubMed ID: 28526967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.